The pharmaceutical industry is entering a new era of inhalation manufacturing as Metered Dose Inhalers (MDIs) shift from traditional high‑GWP propellants

In pharmaceutical manufacturing, most compliance failures originate long before production begins. More than 70% of critical FDA observations are linked to facility design flaw issues embedded in layout, zoning, HVAC, and utilities.

Pharmaceutical companies increasingly prefer facilities capable of manufacturing MDIs, DPIs, Nasal sprays, and Nebulizer solutions within a single integrated setup. This approach reduces capital expenditure, accelerates product diversification, and centralizes quality systems.

Injectable products whether LVPs, SVPs, or dry‑powder injectables operate within the most stringent regulatory and operational frameworks in the pharmaceutical industry. Sterility, particulate control, equipment compatibility, and aseptic workflow make technology transfer for injectables significantly

Inhalation therapies deliver drugs directly to the lungs, making them highly sensitive to particle size, device performance, and patient handling. Because of this, both USFDA and EMA treat inhalation products as complex drug–device combinations, requiring deeper evaluation than conventional oral dosage forms.